GlassScriptPhysician profile
Kenneth J Ramsey
NPI 1770568362
$5,624.90
in general payments reported to CMS, 2019-2025
38 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,531 · 2020: $654 · 2021: $755 · 2022: $247 · 2023: $616 · 2024: $353 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,372.59 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $684.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $632.47 | 2019-2021 | |
| Pfizer INC. | $287.21 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.72 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $244.04 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $230.89 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $195.32 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $188.63 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $136.03 | 2019-2023 | Camzyos |
| Abbott Laboratories | $132.84 | 2020 | |
| Esperion Therapeutics, INC. | $127.12 | 2021 | |
| Medtronic, INC. | $113.72 | 2021-2025 | Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $104.60 | 2021-2024 | Verquvo |
| Heartflow, INC. | $92.51 | 2023-2025 | Ffrct |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $91.59 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $83.39 | 2019 | |
| Medtronic Vascular, INC. | $77.40 | 2020 | |
| Lantheus Medical Imaging, INC. | $59.64 | 2019 | |
| Lilly USA, LLC | $55.91 | 2022 | |
| Gilead Sciences, INC. | $50.72 | 2019 | |
| Lundbeck LLC | $43.90 | 2019 | |
| Edwards Lifesciences Corporation | $40.22 | 2019 | |
| Zoll Circulation INC | $38.00 | 2023 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Kowa Pharmaceuticals America, INC. | $29.68 | 2019 | |
| Inspire Medical Systems, INC. | $29.36 | 2025 | Inspire |
| Abbvie INC. | $29.01 | 2023 | |
| Novo Nordisk INC | $27.30 | 2020-2021 | |
| Scpharmaceuticals INC. | $23.20 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $22.75 | 2019 | |
| Vifor Pharma, INC. | $22.63 | 2019 | |
| Sanofi Pasteur INC. | $18.40 | 2023 | |
| Irhythm Technologies, INC. | $16.22 | 2019 | |
| Chiesi USA, INC. | $14.23 | 2019 | |
| Dexcom, INC. | $12.71 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.06 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.09 | 2021 | |
| Cvrx, INC. | $10.83 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.